Dianthus Therapeutics (DNTH) Price & Analysis

Compare

384 Followers

DNTH Stock Chart & Stats

Day’s Range― - ―

52-Week Range$13.37 - $40.16

Previous CloseN/A

Volume29.07K

Average Volume (3M)932.54K

Market Cap

$1.39B

Enterprise Value$411.31M

Total Cash (Recent Filing)$257.39M

Total Debt (Recent Filing)$1.33M

Price to Earnings (P/E)―

Beta1.26

Next Earnings

Nov 06, 2025

EPS Estimate

-0.89

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.88

Shares Outstanding39,816,223

10 Day Avg. Volume665,878

30 Day Avg. Volume932,539

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.30

Enterprise Value/Revenue84.74

Enterprise Value/Gross Profit86.50

Enterprise Value/Ebitda-3.17

Forecast

1Y Price Target

$68.83

Price Target Upside96.99% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering15

Bulls Say, Bears Say

Bulls Say

Clinical Trial ResultsDianthus released positive clinical data from its Phase II MaGic study investigating its active C1s inhibitor claseprubart for the treatment of generalized myasthenia gravis.

Efficacy And SafetyBoth doses of the active C1s inhibitor led to rapid and clinically meaningful symptom improvement, with a safety profile generally comparable to placebo.

Bears Say

Label RisksA claseprubart label will include the risks of developing autoimmune diseases such as SLE, but the risk will be noted as theoretical.

Market ReactionThe muted reaction in the stock is due to the anti-nuclear antibody cases and questions on the selection of doses for Phase III.

Dianthus Therapeutics News

Short Report: Dave & Busters bears boost exposure

Welcome to this week’s installment of “The Short Interest Report” – The Fly’s weekly recap of short interest...

13d ago

AAOI

DNTH

3 Best Stocks to Buy Now, 9/17/2025, According to Top Analysts

Which stocks are best to buy now? According to Top Wall Street Analysts, the three stocks listed below...

18d ago

DNTH

Dianthus initiated with a Buy at Clear Street

Clear Street analyst Bill Maughan initiated coverage of Dianthus (DNTH) with a Buy rating and $100 price target...

19d ago

DNTH

Dianthus price target raised to $65 from $52 at Stifel

Stifel analyst Alex Thompson raised the firm’s price target on Dianthus (DNTH) to $65 from $52 and keeps...

23d ago

DNTH

Dianthus price target raised to $44 from $42 at Wedbush

Wedbush raised the firm’s price target on Dianthus (DNTH) to $44 from $42 and keeps an Outperform rating...

23d ago

DNTH

Dianthus 6.49M share Secondary priced at $33.00

The deal size increased to $214.5M from $150M and priced below last closing price of $35.57. Jefferies, TD...

25d ago

DNTH

Dianthus price target raised to $63 from $56 at Raymond James

Raymond James raised the firm’s price target on Dianthus (DNTH) to $63 from $56 and keeps an Outperform...

26d ago

DNTH

Dianthus price target raised to $67 from $50 at Baird

Baird raised the firm’s price target on Dianthus (DNTH) to $67 from $50 and keeps an Outperform rating...

26d ago

DNTH

Closing Bell Movers: Nebius up over 40% on Microsoft deal

In the opening hour of the evening session, U.S. equity futures are up marginally, with S&P 500, Nasdaq...

27d ago

APP

Dianthus announces $150M common stock offering

Dianthus (DNTH) Therapeutics announced that it has commenced an underwritten public offering of $150M of its shares of...

27d ago

DNTH

Dianthus price target raised to $100 from $92 at Guggenheim

Guggenheim analyst Yatin Suneja raised the firm’s price target on Dianthus (DNTH) to $100 from $92 and keeps...

27d ago

DNTH

Dianthus Therapeutics Raises $270M Through Stock Offering

The latest announcement is out from Dianthus Therapeutics ( ($DNTH) ). On September 9, 2025, Dianthus Therapeutics, Inc....

24d ago

DNTH

Promising Phase II Results and Market Potential Drive Buy Rating for Dianthus Therapeutics

Rami Katkhuda, an analyst from LifeSci Capital, maintained the Buy rating on Dianthus Therapeutics. The associated price target...

27d ago

DNTH

Promising Clinical Data and Strategic Plans Support Buy Rating for Dianthus Therapeutics

Analyst Maury Raycroft of Jefferies maintained a Buy rating on Dianthus Therapeutics, with a price target of $51.00....

27d ago

DNTH

DNTH FAQ

What was Dianthus Therapeutics’s price range in the past 12 months?

Dianthus Therapeutics lowest stock price was $13.37 and its highest was $40.16 in the past 12 months.

What is Dianthus Therapeutics’s market cap?

Dianthus Therapeutics’s market cap is $1.39B.

When is Dianthus Therapeutics’s upcoming earnings report date?

Dianthus Therapeutics’s upcoming earnings report date is Nov 06, 2025 which is in 32 days.

How were Dianthus Therapeutics’s earnings last quarter?

Dianthus Therapeutics released its earnings results on Aug 07, 2025. The company reported -$0.88 earnings per share for the quarter, missing the consensus estimate of -$0.872 by -$0.008.

Is Dianthus Therapeutics overvalued?

According to Wall Street analysts Dianthus Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Dianthus Therapeutics pay dividends?

Dianthus Therapeutics does not currently pay dividends.

What is Dianthus Therapeutics’s EPS estimate?

Dianthus Therapeutics’s EPS estimate is -0.89.

How many shares outstanding does Dianthus Therapeutics have?

Dianthus Therapeutics has 39,816,223 shares outstanding.

What happened to Dianthus Therapeutics’s price movement after its last earnings report?

Dianthus Therapeutics reported an EPS of -$0.88 in its last earnings report, missing expectations of -$0.872. Following the earnings report the stock price went down -2.037%.

Which hedge fund is a major shareholder of Dianthus Therapeutics?

Currently, no hedge funds are holding shares in DNTH

Dianthus Therapeutics Stock Smart Score

Outperform

Fundamentals

Return on Equity

-34.71%

Trailing 12-Months

Asset Growth

-11.62%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Dianthus Therapeutics

Dianthus Therapeutics, Inc. operates as a clinical-stage biotechnology company that designs, develops, and delivers novel monoclonal antibodies for people living with severe autoimmune and inflammatory diseases. It develops DNTH103 that is in phase 1 clinical trails in patients with generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was incorporated in 2015 and is based in New York, New York.

Dianthus Therapeutics (DNTH) Earnings & Revenues

Historic Earnings Reports

DNTH Stock 12 Month Forecast

Average Price Target

$68.83

▲(96.99% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"15":"$15","58":"$58","101":"$101","36.5":"$36.5","79.5":"$79.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":100,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$100.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":68.83,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$68.83</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":40,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$40.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[15,36.5,58,79.5,101],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,23.85,29.70769230769231,35.565384615384616,41.42307692307693,47.28076923076924,53.13846153846154,58.99615384615385,64.85384615384615,70.71153846153847,76.56923076923078,82.42692307692309,88.28461538461539,94.1423076923077,{"y":100,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,23.85,27.310000000000002,30.770000000000003,34.230000000000004,37.69,41.150000000000006,44.61,48.07,51.53,54.99,58.45,61.910000000000004,65.37,{"y":68.83,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,23.85,25.092307692307692,26.334615384615386,27.576923076923077,28.81923076923077,30.06153846153846,31.303846153846152,32.54615384615384,33.78846153846154,35.03076923076923,36.27307692307692,37.51538461538462,38.75769230769231,{"y":40,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":28.83,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.88,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.01,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.7,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.8,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.15,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.6,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.83,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.7,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.53,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.96,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.59,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.85,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >